RxDoctor Payments DataLook up a doctor →

Ken Haberman, MD

Urology · Federal Way, WANPI 1225290489

Payments from drug & device makers

$47,478in general payments, 2019–2025

Across 344 payments — averaging $138.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verathon Inc.$38K
  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$967
  • Dendreon Pharmaceuticals LLC$735
  • Johnson & Johnson$640
  • Myriad Genetic Laboratories, Inc.$475
  • plus $5K from 44 others

What the payments were for

  • Consulting fees$38,40681%
  • Travel & lodging$8572%
  • Food & beverage$7,82116%
  • Education$3941%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,478 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$260,312
Medicare patients
413
Services billed
4,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide68$974,541
MyrbetriqMirabegron240$177,831
OrgovyxRelugolix57$150,349
GemtesaVibegron50$41,828
Mirabegron ErMirabegron21$17,274
Tamsulosin Hcl561$7,397
Finasteride440$4,916
Trimethoprim63$3,034
Dutasteride54$2,441
Alfuzosin Hcl ErAlfuzosin Hcl119$2,385
Silodosin17$2,383
Estradiol36$2,342
Potassium Citrate ErPotassium Citrate47$2,207
Solifenacin Succinate53$1,427
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$1,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$967$1,152,372308 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$211$192,177107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Washington.

Other urology in Federal Way

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →